1University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; 2National Taiwan University Hospital, Taipei, Taiwan; 3Clinique Médicale du Quartier Latin, Montréal, Québec, Canada; 4Saint Michael’s… Click to show full abstract
1University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA; 2National Taiwan University Hospital, Taipei, Taiwan; 3Clinique Médicale du Quartier Latin, Montréal, Québec, Canada; 4Saint Michael’s Medical Center, Newark, NJ, USA; 5Hospital Vall d'Hebron, Barcelona, Spain; 6Klinikum der Universität München, Munich, Germany; 7ASST Papa Giovanni XXIII, Bergamo, Italy; 8Men’s Health Foundation, Los Angeles CA, USA; 9ViiV Healthcare, Brentford, UK; 10ViiV Healthcare, Research Triangle Park, NC, USA; 11GlaxoSmithKline, Stockley Park, UK Initial Viral Load Decline and Response Rates by Baseline Viral Load Strata With Dolutegravir Plus Lamivudine Versus Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Results From the GEMINI Studies
               
Click one of the above tabs to view related content.